After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and ...

Valneva’s chikungunya vaccine Ixchiq has been greenlit by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) ...

Researchers are enhancing the best features of AAV capsids and overcoming their limitations to accelerate gene-based therapies.

UK MHRA grants marketing authorization to Valneva’s chikungunya vaccine, Ixchiq: Saint Herblain, France Thursday, February 6, 2025, 12:00 Hrs [IST] Valneva SE, a specialty vacci ...

Healthcare-associated infections (HAIs) pose a persistent and tremendous threat to patient safety, having claimed 72,000 patients during their hospitalization according to the Centers for Disease ...

There's plenty of evidence that systemic administration of AAV vectors can cause damage to ... up as more and more countries where it is approved – 43 and counting – agree to reimburse treatment.

DF&TR airport value sales across the European continent were up 7% in Q3 2024 versus the same period pre-Covid (Q3 2019), ...

The U.S. Food and Drug Administration has approved Genentech's Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular ...

The U.S. Food and Drug Administration has approved Axsome Therapeutics' Symbravo (meloxicam and rizatriptan) for the acute ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...

For the first time in two decades, the Food and Drug Administration (FDA) has approved a new class of medication that provides an alternative to addictive opioids for patients looking to manage ...

The FDA has approved Avtozma® (tocilizumab-anoh), a biosimilar to Actemra®, in both intravenous and subcutaneous formulations.